FAIR VALUE - Narrative (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2024 USD ($) Rate	Mar. 31, 2023 USD ($)	Dec. 31, 2023 USD ($)	Jul. 31, 2023 USD ($)
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Change in fair value of contingent consideration	$ 0	$ 9,167
Derivative liability	308		$ 308
Change in fair value of embedded derivative liability	0	$ 0
Level 2
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Debt conversion option value	33,800		35,700
Convertible notes, par value	$ 40,000		40,000
Revenue Volatility
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input	0.15
Discounted Cash Flow | Discount Rate
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input	0.055
Discounted Cash Flow | Credit Spread
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration, measurement input	0.092
Option Pricing Model | Credit Spread
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Embedded derivative liability, measurement input	0.088
INDOCIN
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration	$ 2,700		2,700
Contingent payment consideration, future royalties covenant, product net sales (over)	$ 20,000
Contingent consideration, royalty percentage | Rate	20.00%
Spectrum Pharmaceuticals, Inc.
Schedule of Cash and Cash Equivalents and Marketable Securities [Line Items]
Contingent consideration	$ 0		$ 0	$ 3,932
Change in fair value of contingent consideration	$ 0